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ABSTRACT OF THESIS

DIAGNOSIS OF SYSTEMIC INFLAMMATION USING TRANSENDOTHELIAL
ELECTRICAL RESISTANCE AND LOW-TEMPERATURE CO-FIRED
CERAMIC MATERIALS
Systemic inflammation involves a complex array of cytokines that
can result in organ dysfunction. Mortality remains high despite the vast
amount of research conducted to find an effective biomarker. The cause of
systemic inflammation can be broad and non-specific; therefore, this research
investigates using transendothelial electrical resistance (TEER)
measurements to better define systemic inflammatory response syndrome
(SIRS)/sepsis within a patient. Results show a difference in TEER
measurements between healthy individuals and SIRS-rated patients. This
research also displays correlations between TEER measurements and
biomarkers currently studied with systemic inflammation (tumor necrosis
factor-α, C- reactive protein, procalcitonin). Furthermore, this research also
presents the groundwork for developing a microfluidic cell-based biosensor
using low temperature co-fired ceramic materials. An LTCC TEER-based
microfluidic device has the potential to aid in a more effective treatment
strategy for patients and potentially save lives.
KEYWORDS: Transendothelial Electrical Resistance, Sepsis, Systemic
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CHAPTER 1
INTRODUCTION
A. BACKGROUND
In recent years, extensive research has been conducted to better
understand systemic inflammatory response syndrome (SIRS). SIRS is defined
as a severe response to an insult that triggers a systemic acute inflammatory
reaction. When SIRS is caused by a severe infection, it is classified as sepsis.
Since SIRS is a syndrome that arises from a wide variety of pathological cues
(e.g., sepsis, ischemia, trauma), there is currently no biomarker available for
detecting SIRS.1 Further, the current symptoms that define a patient as having
SIRS does not effectively correlate with the patient’s outcome.2,3 Any of these
pathological cues (infection, ischemia, trauma, etc.) can trigger a response in the
immune system, which initially maintains the vascular integrity. However, the
immune system can start to produce too many cytokines, thereby creating a
harmful environment which leads to the loss of vascular integrity and organ
dysfunction.4,5 In order to streamline the diagnosis and treatment of SIRS, it
would be beneficial to develop a device that could effectively measure the
vascular response of the patient’s circulatory system in “real-time”. It is
hypothesized that an endothelial cell-based biosensor will react to the imbalance
of cytokines and provide a novel diagnostic aid, assisting the clinician in the rapid
detection, and staging of SIRS/sepsis prior to the presentation of physiological
symptoms (fever, heart rate, hypotension, etc.).
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The endothelium is a monolayer of confluent endothelial cells (ECs) that
line the circulatory system. This monolayer acts as a barrier that regulates the
flow of molecules throughout the body. The primary way to analyze an EC
monolayer is through its barrier properties. Barrier properties of ECs are
primarily maintained by the formation of tight junction and adheren junction
protein complexes between the cells in the monolayer. The dynamic modulation
of endothelial permeability, regulated by these junctions, can be quantified
through the use of resistance measurements.6-9 Studies have shown that when
these cells are exposed to increased proinflammatory cytokines, which have
been shown to be upregulated in patients with SIRS 10, a disruption of these
junctions will occur causing a decrease in resistance allowing for stratification of
varying degrees of endothelium dysfunction. It is hypothesized that this change
in resistance could aid in the diagnosis of SIRS and ultimately in the formulation
of an appropriate treatment strategy.
A common method employed in biomedical/pharmaceutical research to
measure changes in endothelial cell permeability includes well plate studies.
Due to the need for large sterile testing equipment like a laminar flow hood as
well as trained personnel to run these studies, they are not practical for the
clinical atmosphere. The incorporation of microfluidics into these static,
commonly used techniques will allow for testing in a closed, controlled
environment. Microfluidic technology also allows the use of small sensing
elements that can produce greater sensitivity. Glass and ceramics have been
widely used in biomedical applications for their chemical inertness, ability to be
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sterilized, and robust mechanical properties.11 Separately, ceramics have been
applied in electronic applications for similar reasons (eg- high electrical resistivity,
hermeticity, and durability).12 In particular, low temperature co-fired ceramics
(LTCCs) combine many of the above features in microfluidic systems with
electronic elements leading to an all-in-one multiple application device. Such a
device has the potential to analyze multiple scenarios within the circulatory
system simultaneously, which can lead to more effective studies and ultimately
produce better patient outcomes.
B. INNOVATION
Since the causes of SIRS are broad and non-specific, the goal of this
research is to show endothelial cells’ innate response to the uncontrolled
cascade of the cytokine storm that is produced during SIRS/sepsis can be
measured using transendothelial electrical resistance measurements.
Furthermore, these measurements can effectively detect SIRS/sepsis within a
patient.
Chapter 2 will review literature on endothelial cell junctions, SIRS, sepsis,
biomarkers studied with SIRS/sepsis, and biosensors. Chapter 3 will discuss the
TEER and biomarker studies performed on septic serums. Chapter 4 will
address the research on developing a microfluidic cell-based biosensor using low
temperature co-fired ceramic materials. By incorporating microfluidics, this
research can enable continuous aseptic testing of endothelial cell permeability
with the capability of generating automated results thereby reducing the need for
trained personnel. Chapter 5 will talk about the conclusions of these studies.
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CHAPTER 2
LITERATURE REVIEW
A. ENODTHELIAL CELL JUNCTIONS AND INFLAMMATION
The vascular endothelium is composed of an endothelial cell monolayer
that lines the inner surface of a person’s entire circulatory system, separating the
underlying tissue from the circulating blood and helping to maintain vascular
homeostasis. The endothelium is in charge of regulating the flow of blood,
nutrients, and multiple types of biologically active molecules. Basal permeability
throughout the endothelium varies since there are various physical properties
and flow rates in the circulatory system. Research has shown in post capillary
venules to be more permeable than capillaries and arterioles, with arterioles
being the least permeable.13 Endothelial cell permeability can occur either
through the cell (transcellular) or between cells (paracellular). Paracellular
permeability deals with the disruption of the junctions between two adjacent
endothelial cells.14 Paracellular permeability is highly regulated by adheren
junction (AJ) and tight junction (TJ) protein complexes as seen in Figure 1.
These protein complexes depend upon complex interactions amongst
cytoskeletal rearrangement, junction adhesion molecules, and cellular adhesive
forces.15-17 TJ protein complexes are formed from occludin, claudins, junction
associated molecules (JAMs), and zonula occludens (ZO) proteins.13,17,18
Claudin-5 is specific to endothelial cells.17 ZO-1 proteins bind the JAMs,
occludin, and claudin protein to the actin cytoskeleton. AJ protein complexes are
formed from cadherin proteins interacting with catenins.13,14,17,19 In endothelial
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Figure 1: Interactions of the proteins associated
with AJs and TJs
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cells, cadherin interacts with cytoplasmic proteins (α-, β-, γ-catenin, p120).
These proteins anchor vascular endothelial (VE)-cadherin to the actin
cytoskeleton.13,14,17,19 Research has been conducted in order to understand the
way in which these junctions function. One study shows the E-twenty six (ETS)related gene controling endothelial cell TJ stability through transcriptional
regulation of claudin-5 as indicated in increased permeability and reduced
expression of claudin-5 when the ETS-related gene was knockdown.17 Another
study indicates that specific cell lines are controlled by different pathways. In this
study, human dermal microvascular endothelial cells (HDMECs) are TJ regulated
through the expression and organization of claudin-5, while human umbilical vein
endothelial cells (HUVECs) are AJ controlled via VE-cadherin.13 Another study
shows the importance of the connection between JAMs (specifically CD31) over
their signaling functions in endothelial cell barrier integrity.16
Vascular inflammation has been shown to occur in rheumatoid arthritis,
atherosclerosis, diabetes, acute lung injury, acute respiratory distress syndrome,
SIRS, and sepsis.4,14,16,17,20-22 Inflammation can lead to increased endothelial cell
permeability. Once vascular stability is compromised, the interstitial space is
filled with a collection of plasma and cells. Many pro-inflammatory stimuli like
cytokines have been shown to disrupt junctions between endothelial cells and
cause cytoskeleton rearrangement. Factors such as histamine, thrombin,
vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α),
and interleukins (IL-1,-6,-8,-10) can lead to gap formation.14,17,18,23 Studies have
shown rapid disruption of the endothelial cell barrier due to exposure from the
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factors thrombin and histamine.17 On the other hand, factors like TNF-α and
endotoxins have been shown to cause a gradual change that occurs over the
course of several hours.14,17 One study shows PIP3 dependent Rac Exchanger 1
is activated downstream of TNF-α. This study also shows that targeting it can
potentially protect vascular inflammation induced by TNF- α and
lipopolysaccharide.14 Additional research has also been conducted in an attempt
to further the understanding of these factors on endothelial cell barrier
dysfunction.14,16,18-20,23 However, time and time again these articles state that the
mechanism in which these factors cause endothelium dysfunction is either too
complex or not clearly understood. An improved understanding of these
mechanisms can lead to the development of novel treatment to prevent
endothelial cell permeability caused by various diseases. Unfortunately, there is
a current demand for rapid detection of such diseases, and the understanding of
these mechanisms is not complete. This research suggests the use of
endothelial cells’ innate response in order to better define and detect such
diseases.
B. SIRS AND SEPSIS
Systemic inflammatory response syndrome (SIRS) has been shown to be
present in one third of in-hospital patients, greater than 50% of ICU patients, and
greater than 80% of surgical ICU patients with mortality rates nearing 20%.24,25
Patient are diagnosed with SIRS when they exhibit at least two of the following
symptoms: 1) temperature above 100.4F or below 96.8F, 2) heart rate in
excess of 90 beats per minute, 3) respiratory rate greater than 20 breaths per
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minute or arterial carbon dioxide tension (PaCO2) below 32 mm Hg, and 4)
abnormal white blood cell count. Studies have shown cytokine levels to increase
as the severity of SIRS increases. 2,3,10,26,27 The cause of SIRS is broad,
involving insults such as: trauma, inflammation, infection, ischemia, surgical
procedures, or any combination of these. There is currently no gold standard
biomarker for the detection of SIRS1; by definition SIRS attempts to define a wide
range of patient immune responses to wide range of injuries.
When SIRS is caused by a severe infection, it is classified as sepsis.
Sepsis is a complex and dynamic disorder. Research has shown sepsis leads to
elevated levels in cytokines; this proinflammatory environment results in severe
deregulations of various systems throughout the body.4,16,22,28 To keep
inflammatory diseases in check, vascular permeability must be strictly regulated.
Current treatment for sepsis includes targeting specific pathogens with
antimicrobials.22 The problem with antimicrobial treatment is that time is needed
to identify the specific pathogen; time the patient does not have. Another
possible treatment for sepsis is to modulate the patient’s immune system.22 The
problem with this approach is that our knowledge regarding inflammation is in its
infancy and response varies greatly from patient to patient.
After the onset of an infection or trauma, cytokines are produced in order
to provoke an inflammatory response from the immune system.4,28 This
response is typically beneficial and necessary for maintaining vascular stability;
however, when it gets out of control, it can be harmful and potentially lifethreatening. The immune response, when uncontrolled, has been defined as the
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“cytokine storm”. During the cytokine storm, massive amounts of cytokines are
circulated throughout the body which can cause organ dysfunction.5 This
overactive immune response can lead to the increased severity of SIRS/sepsis,
multiple organ dysfunction syndrome (MODS), shock, and even death.2,3,10
When SIRS/sepsis progresses and induces MODS, the mortality rate increases
to above 50%.
C. SIRS AND SEPSIS MARKERS
Many biomarkers have been studied in an attempt to effectively predict the
severity of inflammation as well as patient outcome. Some studies point to
cytokine concentrations as being effective biomarkers. One such study
examined how inflammation evolves during early phase sepsis by measuring
multiple cytokines. Using cecal ligation and puncture (CLP) in animals to
emulate polymicrobial human sepsis, this study found that early death (within five
days) could be predicted within 24 hours via increased levels of both pro- and
anti-inflammatory cytokines. However, after five days, they were unable to
accurately predict the outcome.27 Another study compared multiple cytokine
levels and the Acute Physiology and Chronic Health Evaluation (APACHE) II
score of 174 patients meeting the SIRS criteria. This research indicated an
increase in all cytokine concentrations in patients with SIRS; IL-6 was most often
correlated with increased severity as well as poor outcomes.26 A review of
Medline articles searching for the mechanisms involved in SIRS development
looked at data from both animal models and human studies. This review
concludes that both pro- and anti- inflammatory cytokines are released after
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injury; furthermore, the way in which these cytokines excite the immune system
is too complex and unpredictable.10
Procalcitonin (PCT) and C-reactive protein (CRP) have been the most
widely studied biomarkers for sepsis. A study of 18 patients being examined daily
for the presence/absence of SIRS in connection to CRP concentrations reports
no difference in CRP concentrations between patients with multiple or single
occurrences; additionally a decrease of 25% in CRP values from the day before
signifies the end of a septic episode.29 Another study followed 23 ICU patients
each day and classified them according to their infectious status. The results
indicated that CRP values were significantly lower in patients that were
“negative” or “unlikely” to have an infection when compared to those that were
“probable” or “definite”.30 Research was also conducted over a 15 day period on
a population of 40 patients diagnosed with systemic inflammation and MODS.
The collected data included PCT, CRP, Sequential Organ Failure Assessment
(SOFA) score, APACHE II score, and survival. This study shows that CRP
concentrations were raised in all the SOFA scores and PCT concentrations
increased significantly with higher SOFA scores. Furthermore, CRP values were
similar between survivors and non-survivors whereas non-surviving patients
produced a significant increase in PCT values indicating that PCT provides more
information on the severity of the inflammation than CRP.31 Another study
compared PCT, CRP, and infection on 150 ICU patients being examined for 10
days. This research indicates PCT and CRP concentrations were higher in
patients with an infection; additionally, PCT was a better marker for
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approximating the severity, prognosis, and time course of infection.32 However,
research on the daily PCT and CRP values of 190 ICU patients contradicts these
previous studies stating that CRP concentrations have a higher sensitivity and
specificity when compared to PCT. This study also concludes that while PCT
values were significantly higher in non-survivors, CRP values were not.33 A
review of Pubmed articles searching combinations of PCT, critical(ly), intensive,
biomarkers, and sepsis focused on publications from 2000-2010 supporting the
claim that PCT concentrations are a better marker for sepsis than CRP. This
review determined that PCT is more effective in ruling out systemic sepsis than
confirming infection and that recent evidence suggests PCT values could give
effective aid in the length of antibiotic treatment.34 Another review of over 3,000
studies in the Medline database when searching for “sepsis” and “biomarker”
indicates that 178 biomarkers have been evaluated experimentally, clinically, or
both. This study reports that all of these biomarkers lack the specificity and/or
sensitivity necessary to be used as a single biomarker for developing treatments;
however, combinations of these biomarkers may be more effective.35
Regardless of the extensive research, clinical trials using antiinflammatory treatments for SIRS/sepsis have resulted in failure.4,22 A recent
study of over 1,800 patients suggests that the classic model of using anticytokines for treatment is impractical because cytokine activation progresses
longer than the model anticipated. Furthermore, by the time most patients
pursued treatment, the cytokine cascade was in full effect. Furthermore, the
patients who had a higher risk of developing severe sepsis and mortality had
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higher concentrations of both proinflammatory AND anti-inflammatory cytokines.
This indicates that targeting cytokines might not be beneficial in treatment
therapies.28 Additionally, contradicting studies show that PCT and CRP are
unable to solely distinguish between SIRS and sepsis or predict patient
outcome.31,33 Most of the studies suggest PCT values are indicative of the
severity of sepsis and can aid in antibiotic treatment.31,32 Some studies have
also shown that following recovery from the initial trauma, a patient’s life is more
easily threatened when exposed to a minor second incident of SIRS.7
Unfortunately, an ideal biomarker will not likely be discovered for sepsis in the
near future due to the complexity of the disease. However, a cell-based
biosensor evaluating a cell’s intrinsic response to the inflammatory agents
produced in real-time has the potential to better define SIRS/sepsis by way of
vascular dysfunction, as well as aiding in the rapid diagnosis and treatment
before the patient’s life is threatened.
D. BIOSENSORS
The medical diagnostic field can be greatly expanded through the use of
cell-based biosensors. Cell-based biosensors are devices that use living cells as
sensing elements. One benefit of cell-based biosensors is their ability to provide
insight into complex and potentially unknown physiological cell receptor-ligand
interactions that occur in disorders such as SIRS. Research has shown an ability
to alter cellular DNA so that it fluoresces in the presence of cytokines, but there is
no correlation between the concentrations of cytokines and the luminescence
intensities .36,37 Studies have also shown an ability to detect changes in
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transcellular permeability using fluorescent tags. A study was conducted where
an array of HUVEC monolayers were grown on a microporous membrane which
was located between a polydimethylsiloxane (PDMS) layer and a glass
substrate. Microchannels and microvalves perfused fluorescein isothiocyanate
conjugated (FITC) albumin and measured the permeability of the HUVEC
monolayers by measuring fluorescent intensities.38 Other studies generated
microfluidic chips to apply fluid flow to endothelial cells while analyzing
permeability using FITC albumin. These studies indicate an ability to test
endothelial permeability under physiologically relevant shear stresses.39,40
However, this type of analysis can become expensive and requires large
fluorescent equipment not desired or practical in each ICU room.
Biosensors using electrical analysis methods such as transendothelial
electrical resistance (TEER)6,7,41-43, electrical cell substrate impedance
spectroscopy (ECIS)8,9,44-49, electrochemical impedance spectroscopy (EIS)50-52,
and ion sensitive electrodes (ISE)53 have shown the ability to retrieve information
rapidly regarding the response of cells. One study presented TEER
measurements being used to show that reactive oxygen species produced during
hypoxia regulates secretion of cytokines that can induce endothelial
permeability.41 Another study demonstrated how a cost-effective EIS for cytokine
IL-12 could be used for diagnosis of diseases with known biomarkers in realtime.52 The ECIS has been established as a great way to analyze endothelial
cells using impedance. It has been used to correlate endothelial cell permeability
to cytochalasin B49, ZO-1 protein45, rickettsial infection54, and even establish
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synthetic histatins as a skin wound-healing agent47. The ISE has shown that a
cell-based biosensor can be used to detect and differentiate between the
existences of small quantities of cytokines that correlate with stages of cancer.53
Each of these devices has also shown accurate cellular responses due to
proinflammatory cytokines.6,41,52-55 They have the ability to provide the quick,
broad range, natural cell permeability response desired in a disease like
SIRS/sepsis. These simple techniques when performed statically are effective.
However, they do not analyze cells in their natural environment.
Since research shows that ECs have the ability to change physically with
their environment56-59, the incorporation of microfluidic technology can allow cell
based diagnostic methods to be used in controlled conditions and a closed sterile
environment with constant nutrient and waste removal during experimentation;
this removes the need for trained personnel and large testing equipment.60 The
use of microfluidics analyzes a smaller sample size which is advantageous since
anemia is a concern in the ICU.71 Microfluidic systems also have the capability to
apply physiological shear stress with a constant laminar flow, replicate cellular
environments, and function with automated processing.38,61-66 Microfluidic
devices have become tools for analyzing and expanding research in: DNA
analysis, chemical synthesis, cellular analysis, protein analysis, biochemical
analysis, electrokinetic separation, biomedical monitoring, and clinical
diagnostics.61-63,67 Transendothelial electrical resistance measurements have
shown an ability to effectively analyze endothelial barrier function without the cost
of fluorescent tags. Some studies have incorporated this technique into the
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microfluidic world. One such study constructed a microfluidic TEER chip by
sandwiching a semiporous membrane between two PDMS channels containing
Ag/AgCl electrodes and was able to successfully monitor changes in TEER
measurements in real-time.68 Another study used bipolar pulse square wave
potential to measure TEER across endothelial cells grown in wells with a
microporous polycarbonate membrane base overtop of a microfluidic channels
containing an aluminum electrode. The results showed an ability to evaluate
endothelial permeability via TEER while interacting with a flowing stream of blood
components; however, the cells in this device are not directly exposed to the
flowing stream of blood.69 A recent study cultured endothelial cells directly onto
small gold electrodes arranged within a flow channel and different shear stresses
were applied to the cells. In this study, TEER measurements were taken during
these shear stresses to determine the change in barrier function. The results
show an increase in resistance while the cells dynamically alter their morphology
in response to an increase in shear stress as well as a drop in resistance as the
shear stress in decreased.70 For electrical impedance measurements used in the
previous study, the microfluidic geometry allows use of smaller sensing elements
leading to a greater change in impedance in the cell monolayer. This can result
in a wider range of detection limits when compared to studies conducted in
macroscopic well plates. One study presents a “trap-and-measure” device that is
able to differentiate between HeLa, A549, MCF-7, and MDA-MB-231 cells by
measuring impedance at multiple frequencies and voltages. This study showed
that cells are unique in their tolerances to electric fields.62
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A multilayered ceramic microfluidic device that incorporates an array of
confluent EC-based sensors to monitor electrical impedance changes can study
endothelial cell permeability in real-time under physiological conditions. The
production of devices with this ceramic material is quicker and simpler than that
of a silicon device as well as being more durable and cost efficient. Most
importantly, the proposed ceramic material can integrate microstructures with
optic and electronic components leading to the analysis of multiple applications
that can be automated within one device.72-75 These ceramic devices have the
potential to analyze multiple physiological scenarios within the circulatory system
simultaneously, which can lead to more effective and efficient EC permeability
studies.
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CHAPTER 3
SEPSIS STUDIES
Due to the complexity of sepsis, an ideal biomarker will not likely be
discovered in the near future; therefore this research looks at a different way of
analyzing the systemic inflammation that occurs with this disease. This chapter
looks at the practicality of a cell-based biosensor evaluating a cell’s intrinsic
response to the inflammatory agents produced in real-time using TEER
measurements. This type of sensor has the potential to better define
SIRS/sepsis by way of vascular dysfunction, as well as aiding in the rapid
diagnosis and treatment before the patient’s life is threatened.
A.) MATERIALS AND METHODS
A-i. CELL CULTURE
The Human umbilical vein endothelial cells (HUVECs) were obtained from
Lonza (Switzerland) at passage 1. The HUVECs were grown in 75 cm2 tissue
culture flasks. EGM-2 media (Lonza) was used to grow the cells inside the flasks
in an incubator at 37ºC and 5%CO2. Once HUVECs were close to confluency
(>85%), they were split and seeded onto Transwell inserts (Corning) at a
concentration of 25,000 cells/cm2. Passages 4-8 were used in these
experiments. Following the seeding of cells, the well plates were placed in the
incubator under the same conditions as the cell culture flasks. For trials lasting
longer than one day, the media was exchanged for fresh media within the first 24
hours post-seeding and then every other day.
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A-ii. TRANSENDOTHELIAL ELECTRICAL RESISTANCE MEASUREMENTS
Transwell inserts (Corning) were filled with media and incubated
overnight. Afterwards, background resistance measurements were obtained
using the Endohm12 TEER cup. HUVECs were then seeded into each insert at
a concentration of 25,000 cells/cm2. Once a confluent layer of HUVECs was
obtained in the inserts (>10 Ω*cm2), the inserts were treated with serum samples
and analyzed with the Endohm12 cup. Measurements were obtained every 5
seconds for the first 12 minutes. Measurements were also obtained at 20 min,
30 min, 1 hour, 4 hours, and after overnight incubation.
A-iii. RAT SERUM STUDIES
The primary validation of the current approach has been demonstrated in
an animal model of SIRS/Sepsis. In collaboration with Drs. Callahan and
Supinski (UK Medical Center), a preliminary proof-of-concept study was
performed using a rat CLP model of sepsis. The ligation of the cecum resulted in
acute polymicrobial peritonitis within the animal.76,77 In this study, 1 mL of blood
was drawn from two healthy animals prior to surgery. The animals were then
sedated and CLP surgery performed. At 24 hours following surgery, another 1
mL blood sample was drawn. Following this, the animals were sacrificed by a
euthanizing dose of Phenobarbital. The blood samples were spun down and the
serum was obtained and stored at -20C immediately. For the TEER study, a 1:1
dilution of the serum into culture media was used. This mixture was then placed
in the luminal portion of a transwell insert containing a confluent HUVEC
monolayer. TEER values were collected at varying time points for an hour. One-
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way ANOVA was used to make comparisons between the blood samples taken
before surgery (healthy control) and after (septic).
A-iv. HUMAN SERUM STUDIES
A-iv-1. HUMAN SERUM STUDY PROCEDURES
Once SIRS-rated samples were obtained, HUVECs were seeded into
Transwell inserts and grown to confluency. When confluent, Healthy serum
(negative control), Healthy serum+histamine (positive control), or SIRS-rated
serum samples were equilibrated to 37C in the incubator and exposed to the
HUVEC monolayer. The healthy serum control was used to display the
response of the endothelial cells to serum without increased inflammatory stimuli.
The healthy serum spiked with 2mM histamine control was used to mimic the
rapid and significant inflammatory response displayed in the rat serum study.
Resistance measurements were obtained every 5 seconds for the 12 minutes.
Measurements were also obtained at 20 min, 30 min, 1 hour, 4 hours, and after
overnight incubation. The data obtained from the inserts exposed to different
SIRS-rated serums were compared to the data obtained when exposed to
healthy serum. The %TEER data is indicative to the endothelial cell monolayer’s
“leakiness” associated with the exposure to the sample. One-way ANOVA was
used to compare the %TEER of the different samples as well as the patient
outcome (e.g. days in ICU/ mortality).
A-iv-2. COLLECTION OF BLOOD
Collaboration was achieved between the medical center and our lab
through the CCTS Pilot: Cell Based Endothelium Activation Potential (EAP)
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Sensor for the Diagnosis and Monitoring of Sepsis, Severe Sepsis, and Septic
Shock. This was essential for this portion of the research as blood samples were
collected from healthy volunteers as well as sick patients. Through the pilot
study, admitted patients were screened for SIRS and fourteen patients were
enrolled. The following criteria was matched with the number of patients
indicated: 1) non-infectious SIRS- 4 patients, 2) sepsis (SIRS + confirmed
infection)- 5 patients, and 3) severe sepsis (sepsis + organ dysfunction)- 5
patients. These criteria were chosen to show the response to increased
inflammation severity. 10 mL of blood was withdrawn by qualified clinic and
nursing staff.
A-iv-3. CLINICAL DEFINITIONS
Subjects were defined as SIRS if they displayed two or more criteria from
Table 1 without an infection. Subjects were defined as septic if they met the
SIRS criteria and were suspected or confirmed to have an infection. Subjects
were defined as severe sepsis if they met the sepsis criteria and displayed one or
more criteria from Table 2.
A-iv-4. BIOMARKER ASSAY
Systemic responses to factors within the blood are complex and patient
dependant. It is unclear if access to precise concentrations of circulating factors
within the blood would benefit in generating effective treatment strategy as many
studies show increased levels of cytokines with many failed anti-cytokine
treatments failing in clinical trials. All samples were analyzed for concentrations
of inflammatory signaling factors displayed in sepsis as well as biomarkers used
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Table 1- SIRS criteria
Temperature

>38ºC or <36ºC

Heart Rate

>90 beats/minute

Respiratory Rate

>20 breathes/minute

PaCO2

<32 Torr

WBC

>12,000 or <4,000 cells/mm3

Table 2- Severe Sepsis criteria
Respirations

PaO2/FiO2

250 Torr

Coagulation

Platelets

<50x103/mm3

Liver

Bilirubin

>4.0 mg/dl

Cardiovascular

Vapressor

prescribed

Renal

Creatinine

>4.0 mg/dl

Oliguria

Urine output

<500 mL/day
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for sepsis. These factors are: tumor necrosis factor-alpha (TNF-α), interleukin-6
(IL-6), interleukin-8 (IL-8), procalcitonin (PCT), C-reactive protein (CRP), and
granulocyte/macrophage colony stimulating factor (GM-CSF). CRP and PCT
concentrations were measured by ELISA (ALPCO and RayBiotech respectively)
assay plates. A milliplex human magnetic high sensitivity panel luminex assay
was used to measure the concentrations of IL-6, IL-8, GM-CSF, and TNF-α.
These assays were conducted and analyzed by trained personnel at the
University of Kentucky biochemical analysis laboratory.
B.) RESULTS
B-i. VALIDATION OF TEER AS PROBE FOR SIRS/SEPSIS
A background resistance (Rb) of each insert and media was obtained
before seeding of the HUVECs. Once the cells were confluent, a baseline
resistance (Rc) was recorded for each insert. Rat serum was then exposed to
the endothelial cell monolayer and resistance measurements (Rt) were taken
after 2.5, 7.5, 15, 30, 60 minutes of exposure. %TEER was calculated by
removing the background resistance for both the baseline and time point
resistances and dividing the time point by the baseline [ (Rt-Rb)/(Rc-Rb)*100
=%TEER ]. The results from the rat CLP study show a quick and significant
decrease in %TEER with septic serum when analyzed against the values of its
healthy counterpart (Figure 2). Figure 2 shows the average %TEER of serum
taken before surgery (Control) on the rats were all above 60% during the first
hour of exposure to the serum while the average %TEER values of the serum
taken after surgery (Septic) were all below 60%. These results indicate an ability
22

Figure 2: Graph showing the change in %TEER of HUVECs for the
first hour after exposure to rat serum before (control) and after
(Septic) CLP
N=3; error bars represent SE; *p<0.05
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to quickly detect the difference between healthy rat serum and rat serum with
increase inflammatory agents caused by CLP using TEER measurements.
B-ii. %TEER RESPONSE SIRS-RATED HUMAN SERUM
The same technique as mentioned earlier was used to calculate %TEER.
The results from the SIRS-rated human serums differed from the rat CLP results.
During the first 30 minutes of exposure to the serum, the data obtained displays
no statistically significant serum difference found between the healthy serum
samples and the SIRS-rated serum samples (Figure 3). Figure 3 does show a
significant difference between the negative control (Healthy) and the positive
control (Healthy+Histamine). After exposing the cells to the serum for an hour,
statistical differences were found in the average %TEER measurements between
the healthy serum samples (147.8%±4.5% SE) and the SIRS (130.2%±6.7%)
and Severe Sepsis (131.3%±5.1%) serum samples (Figure 4). After 4 hours of
exposure, all of the different levels of SIRS-rated samples(SIRS- 102.1%±6.3%;
Sepsis- 97.9%±4.9%; Sev. Sepsis- 96.4%±3.1%) displayed a statistically lower
%TEER value compared to the healthy serum (128.8%±5.3%) (Figure 4). After
overnight incubation only the SIRS (96.6%±7.0%) and severe sepsis
(92.1%±6.0%) samples remained significantly lower than the healthy serum
(123.9%±5.8%). Unfortunately, no significant differences were found between
the different SIRS-rated serums throughout this experiment. These results
indicate an ability to detect the difference between healthy human serum and
human serum with systemic inflammation after an hour of exposure using TEER
measurements.
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Figure 3: Graph showing the change in %TEER for the first 30 minutes of
exposure to serum collected from patients that were healthy or showing
symptoms of SIRS, Sepsis, or Severe Sepsis
N=5 for Healthy,Sepsis,Sev. Sepsis,Healthy+Histamine; N=4 for SIRS;
error bars represent SE
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Figure 4: Graph showing the change in %TEER of exposure to
serum collected from patients that were healthy or showing
symptoms of SIRS, Sepsis, or Severe Sepsis
N=5 for Healthy,Sepsis,Sev. Sepsis; N=4 for SIRS; error bars
represent SE; *p<0.05, compared to control
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B-iii. BIOMARKER ANALYSIS
The results show in Figure 5 from ELISA assays indicate that
concentrations of TNF-α and IL-6 were significantly higher in patients labeled
SIRS (13.6±2.4 SD and 1,096±905 SD respectfully) or severe sepsis (24.5±6.3
and 1,669±661 respectfully) than healthy individuals (7.1±2.2 and 4.4±1.8
respectfully). Furthermore, TNF-α was significantly higher in severe sepsis
patients than SIRS patients. Due to the scatter of the IL-8 (Figure 5C) and GMCSF (Figure 5D) concentrations, no significant differences were found between
healthy individual and sick patients. All of the healthy individuals displayed PCT
levels around or below the detectable limit (10pg/mL) (Figure 5E). The patients
in the SIRS and sepsis categories, however, contained PCT concentrations all
over the spectrum (Figure 5E). Therefore, no significant difference can be seen
between the healthy controls and the patients rated with SIRS or sepsis.
However, there was a significant difference between healthy individuals
(13.2±3.9) and patients under the severe sepsis (1,103±542) criteria due to all of
those patients having elevated PCT levels. All of the sick patients had severely
elevated CRP values (>98.6μg/mL) when compared to healthy individuals
(<8.3μg/mL) (Figure 5F). However, there was no significant difference between
the different SIRS-rated groups. This agrees with literature that CRP
concentrations increase drastically once a patient became ill; however, these
values do not change significantly as the illness progresses.
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Figure 5- Concentrations of A)TNF-α, B)IL-6, C)IL-8, D)GM-CSF, E)PCT, and
F)CRP in patients of different SIRS-rated categories
N=5 for Healthy,Sepsis,Sev. Sepsis; N=4 for SIRS; error bars=SD; *p<0.05
compared to control, #p<0.05 compared to SIRS
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Looking at the patients individually, Table 3 shows the four hour % TEER
measurements correlated the highest to cytokines TNF-α, IL-6, and IL-8 (-0.706,
-0.451, and -0.575 respectfully) as well as biomarkers PCT and CRP (-0.604 and
-0.854 respectfully) while the one hour %TEER measurements correlated the
highest to ICU days (-0.462). Figures 6, 7, 8, and 9 show the significant linear
correlations between %TEER after four hours of exposure to different human
serums and TNF-α, PCT, CRP, and IL-8 concentrations (respectfully). Figures
10, 11, and 12 shows the scatter between %TEER after four hours of exposure
and the time spent in the ICU, IL-6, and GM-CSF (respectfully). Table 4
indicates TNF-α (0.627) as the highest assay correlated to the length of stay in
the ICU. The average stay of SIRS, sepsis, and severe sepsis patients were 6
days, 2 days, and 8 days respectively. One patient out of each SIRS-rated group
passed away. Each of these three patients contained a PCT concentrations
above 1,000 pg/mL, maximum IL-6 concentrations (>2,000 pg/mL), and IL-8
concentrations above 200 pg/mL. None of the survivors met all three of these
criteria. These results indicate taking TEER measurements after four hours as
the time point to differentiate between healthy and SIRS-rated samples.
C.) DISCUSSION
In these studies, a method for assessing systemic inflammation using
transendothelial electrical resistance (TEER) measurements was established.
The rat CLP model displayed an ability to quickly and effectively see a difference
between healthy and septic rat serum. These results indicated that a device
capable of monitoring impedance of endothelial cells in “real-time” can show a
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Table 3- %TEER/Biomarker Pearson Correlation Data
30 min
%TEER
-0.248
ICU Days
(0.355)
-0.380
TNF-α
(0.146)
-0.219
PCT
(0.414)
-0.494
CRP
(0.052)
0.076
IL-6
(0.779)
-0.468
IL-8
(0.067)
-0.308
GM-CSF
(0.247)

1 hr
%TEER
-0.462
(0.072)
-0.551*
(0.027)
-0.375
(0.152)
-0.586*
(0.017)
-0.165
(0.541)
-0.544*
(0.030)
-0.293
(0.271)

4 hr
%TEER
-0.400
(0.124)
-0.706*
(0.002)
-0.604*
(0.013)
-0.854*
(0.000)
-0.451
(0.080)
-0.575*
(0.020)
-0.058
(0.831)

Overnight
%TEER
-0.398
(0.127)
-0.688*
(0.003)
-0.581*
(0.018)
-0.668*
(0.005)
-0.406
(0.118)
-0.377
(0.150)
-0.199
(0.460)

Cell Contents: Pearson correlation
(P-Value)
*p<0.05

IL-6
IL-8
CRP
ICU
Days
TNF-α
PCT

Table 4- Biomarker Pearson Correlation Data
GM-CSF
IL-6
IL-8
CRP ICU Days TNF-α
-0.014
(0.960)
0.346
0.670*
(0.189) (0.004)
0.350
0.491 0.648*
(0.184) (0.053) (0.007)
0.433
0.250 0.579* 0.565*
(0.094) (0.351) (0.019) (0.023)
0.653*
0.248
0.488 0.817*
0.627*
(0.006) (0.355) (0.055) (0.000)
(0.009)
0.250
0.507* 0.423 0.676*
0.441
0.603*
(0.350) (0.045) (0.102) (0.004)
(0.087)
(0.013)
Cell Contents: Pearson correlation
(P-Value)
*p<0.05
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Figure 6- Graph showing %TEER after 4 hours of exposure to serum collected
from patients versus TNF-α concentrations
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Figure 7- Graph showing %TEER after 4 hours of exposure to serum collected
from patients versus PCT concentrations
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Figure 8- Graph showing %TEER after 4 hours of exposure to serum collected
from patients versus CRP concentrations
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Figure 9- Graph showing %TEER after 4 hours of exposure to serum collected
from patients versus IL-8 concentrations
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Figure 10- Graph showing %TEER after 4 hours of exposure to serum
collected from patients versus time spent in the ICU
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Figure 11- Graph showing %TEER after 4 hours of exposure to serum
collected from patients versus IL-6 concentrations
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Figure 12- Graph showing %TEER after 4 hours of exposure to serum
collected from patients versus GM-CSF concentrations
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fast response. It is important to note that this experiment was performed in a rat
model and the serum being analyzed is an extremely severe SIRS/sepsis
specimen. This data corroborates the notion that TEER measurements have the
potential for aiding in SIRS detection and treatment.
It has been reported that cytokines cause an increase in permeability and
a drop in TEER measurements after four hours of exposure. 80 This study
demonstrated such a significant drop in TEER after four hours of exposure to
human serum with increased levels of cytokines. This study also displayed
significant correlations between the %TEER measurements taken after four
hours of exposure to serum and TNF-α, IL-8, PCT, and CRP. The results
gathered by the human serum samples showed a difference in %TEER values
between healthy serum and SIRS-rated serum as early as one hour post
exposure. Unfortunately, the differences in %TEER amongst the different SIRSrated samples were not significant indicating only the ability to detect healthy
serum from unhealthy serum.
It has been reported that SIRS/sepsis causes an increase in TNF-α, IL-6,
IL-8, PCT, and CRP.26, 32 Literature shows TNF-α concentrations are
significantly higher from healthy individuals (10.5±0.7 pg/mL) to SIRS (16.7±1)
and from SIRS to people with severe sepsis (48.4±17).26 The results from this
study demonstrated such a trend from healthy (7.15±2.23 pg/mL) to SIRS
(13.63±2.40) and from SIRS to severe sepsis (24.55±6.34) with similar
concentrations. The literature on IL-6 and IL-8 show an increase in
concentrations between healthy individuals (2.8±0.3 and 20±3 pg/mL) and
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people with SIRS (93±15 and 141±74), sepsis (183±66 and 114±80), and severe
sepsis (409±131 and 325±271).26 The results from this study displayed a low
concentration for healthy people (4.38±1.82 and 11.36±3.40 pg/mL) with
scattered elevated concentrations for SIRS (1,096±905 and 97.27±106.92),
sepsis (900±900 and 116.06±89.68), and severe sepsis (1669±661 and
509.10±745.95). Furthermore, the CRP results from this study show a similar
trend bow low healthy concentrations and elevated SIRS, sepsis, and severe
sepsis (2.06±3.17, 193.6±64.0, 246.4±104.9, 306.4±86.6 μg/mL) to that of
literature values (2.7±1, 109±7, 141±12, 189±17 μg/mL).26 The PCT
concentration reported in literature (healthy-104, SIRS-380, sepsis-1,580, severe
sepsis-5,580)32 are higher than those shown in this study (13.2, 567.7, 526.4,
1,103.0). The scatter of concentrations obtained by the ELISA assays within the
different SIRS-rated categories reflects the inability of the clinician to detect and
stage the SIRS/sepsis criteria.
Overall, this study showed TEER measurements detecting systemic
inflammation. It displayed the trends between % TEER and biomarkers found
with systemic inflammation. Lastly, It demonstrated similar concentrations and
trends between healthy individuals and SIRS-rated serums to that of literature for
biomarkers: TNF-α, IL-6, IL-8, and CRP. These results confirm that a device
monitoring impedance of endothelial cells can effectively detect a difference
between healthy serum and unhealthy serum.
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CHAPTER 4
LOW TEMPERATURE CO-FIRED CERAMIC STUDIES
A.) MATERIALS AND METHODS
A-i. CELL CULTURE AND STAINING
The Human umbilical vein endothelial cells (HUVECs) were obtained from
Lonza (Switzerland) at passage 1. The HUVECs were grown in 75 cm2 tissue
culture flasks. EGM-2 media (Lonza) was used to grow the cells inside the flasks
in an incubator at 37ºC and 5%CO2. Once HUVECs were close to confluency
(>85%), they were split and seeded onto either the test samples, or Transwell
inserts at a concentration of 25,000 cells/cm2. Passages 4-8 were used in these
experiments. Following the seeding of cells, the well plates were placed in the
incubator under the same conditions as the cell culture flasks. For trials lasting
longer than one day, the media was exchanged for fresh media within the first 24
hours post-seeding and then every other day.
The Dulbecco’s phosphate-buffered saline (DPBS) solution used in these
experiments was generated by adding 4g NaCl, 0.5g Na2PO4, 0.1g KCl, and 0.1g
KH2PO4 to 500 mL of DI water from the Milli-Q® Advantage A10 system
(Millipore). The solution was sterilized via autoclave before it was used. The
Live/Dead solution used in these experiments was 0.2 (v/v%) Calcein AM and
0.34 (v/v%) Ethidium Homodimer-1 in DPBS. For imaging, the well or channel
was rinsed once with DPBS to remove loosely affixed cells. The well or channel
was then filled with the Live/Dead solution and incubated for 20-30 minutes.
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A-ii. MATERIAL BIOCOMPATIBILITY
The LTCC materials used were Heralock® HL2000 (Heraeus, West
Conshohocken, PA). Four (3” x 3”) HL2000 layers were laminated together using
a hydraulic press (Model 3851, Carver, Wabash, IN) equipped with heated
platens. The platens were heated up to 70ºC and the layers were placed under
5,000 lbs of pressure for 10 minutes followed up by 10,000 lbs for 15 minutes.
Following the lamination, 1 cm x 1 cm LTCC test samples were patterned via
laser ablation. Three sample sets were created. The first set was only the
HL2000 LTCC material bare, which from here on out will be called “Blank”. The
other two sets had conductive pastes that were then hand painted onto one side
of these HL2000 LTCC test samples. The conductive pastes that were evaluated
are TC0306 (Heraeus) or TC8101 (Heraeus), which from here on out will be
called “silver” and “gold” respectively. After patterning with conductor inks, each
test set was sintered following the recommendations by the manufacturer.
Eighteen HL2000 LTCC test samples were constructed for each sample
set (Blank, Gold, and Silver). Half of each sample set was soaked for 24 hours in
DI H2O from the Milli-Q® Advantage A10 System (Millipore), these samples will
be considered “Leached” samples while the others will be “Unleached”. Each
sample set was placed into a resealable autoclave pouch and was autoclaved to
121ºC for 30 minutes. Afterwards, the pouches were sprayed with 70% ethanol
and placed under a laminar flow hood. The pouches were opened and UV light
was exposed to the surface of the LTCC test samples on for an hour to aid in the
sterilization. Three of each sample set were placed into a 12 well plate and were
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either soaked in 0.5 mL of fibronectin solution at a concentration of 25ìg/mL and
incubated for 45 minutes or not soaked with fibronectin. The fibronectin wells
were then rinsed three times with DPBS and HUVECs were seeded into the wells
as described earlier with three wells on each plate being a control without any
LTCC material. The well plates were then cultured for 1-2 hours to look at the
initial attachment, one day, and three days. Following these culture periods, the
wells were rinsed once with DPBS, stained with Live/Dead solution, and imaged.
The images were analyzed using NIS-Elements BR 3.0 Object Count software.
A-iii. DEVICE FABRICATION AND BIOCOMPATIBILITY
Three simple layers were patterned via laser ablation (top, channel, and
bottom). The top layer contained inlet and outlet ports of 1.5 mm in diameter as
well as an electrode pattern. The channel layer contained a rectangular channel
with dimensions of 4.44 cm x 3 cm x 0.8 cm. The bottom layer contained the
electrode pattern. The electrode pattern was screen-printed onto the top of the
bottom layer and bottom of the top layer. Lamination of the HL2000 LTCC tape
was accomplished using a hydraulic press (Model 3851, Carver, Wabash, IN)
equipped with heated platens. The platens were heated up to 70ºC. Individual
HL2000 layers were placed under 5,000 lbs of pressure for 10 minutes followed
up by 10,000 lbs for 5 minutes. Following this, the layers were then laminated
together at the same temperature under 5,000 lbs of pressure for 10 minutes
followed up by 8,000 lbs for 15 minutes. After laminating the layers together, the
device was sintered following the recommendations by the manufacturer. For
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viewing purposes, a PDMS window was attached via oxygen plasma after
sintering the device (See Figure 13).
The device was soaked in DI H2O to remove leachates. Afterwards, the
device was sterilized via autoclave and UV light exposure. The device was then
filled with media and incubated overnight. Afterwards, the device was soaked in
FN and HUVECs were seeded as previously described. The fittings were filled
with media and the device was placed in the incubator. The media in the
channel was replaced each day with fresh media. At the end, the device was
disconnected, stained with Live/Dead solution, and imaged.
A-iv. DEVICE SENSITIVITY
A waveform generator (Agilent 33220A) was connected to a resistor box
and then to a data acquisition/switching unit (Agilent 34970A) which was
connected to a pair of clips. Data was then transferred to the computer through
the switching unit (see Figure 14). A power supply of 1 volt at a frequency of
1000 Hz was used in these studies. A 100 kOhm resistor was placed into the
resistor box to generate a 10 µA current through the clips.
The LTCC device was then tested for its sensitivity in resistance values
and compared devices currently on the market. The device was compared to the
Endohm12 TEER cup and the STX2 TEER chopsticks (World Precision
Instruments, Sarasota, FL) which are static TEER devices that are commonly
used in research. The resistance values for the STX2 were obtained with an
EVOM2 Voltohmmeter (WPI). The resistance values for the LTCC device were
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Figure 13: Diagram of LTCC device
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Figure 14: Diagram of In-house set-up
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acquired with the Agilent set-up while the resistance values for the En dohm12
were retrieved by both the Voltohmmeter and the Agilent set-up.
A-v. SYSTEM IMPROVEMENTS
The In-house system aided in the start-up of the LTCC device for TEER
measurements as it proved to be beneficial in the detection of an endothelial cell
monolayer. However, the noise of this system was too great to detect small
TEER responses of an endothelial cell monolayer. To reduce this noise, the
Agilent systems were replaced with a Lock-in amplifier (See Figure 15). The
LTCC device was then tested for its sensitivity in resistance values and
compared to the previously obtained data from the In-house system.
The electrode geometry was also altered to generate suitable impedance
graphs of a cell monolayer for TEER detection. The electrode size was reduced
from 4 mm2 rectangles to a 0.05 mm2 circle vias to focus the impedance on the
interface of the electrode. The electrodes (4 mm2 rectangles/0.05 mm2 circles)
were then tested for their ability to detect a “pseudo-cell” (a parallel resistor and
capacitor to mimic a cell monolayer). In this analysis, the LTCC devices were
filled with media and impedance measurements were obtain at varying
frequencies. After obtaining this background impedance, the “pseudo-cell” was
connected in series with the device and impedance measurements were
obtained at the same frequencies.
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Figure 15: Diagram of Lock-in Amplifier set-up
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B. RESULTS
B-i. MINIMAL ATTACHMENT AND GROWTH ON HL2000 LTCC
The biocompatibility images for Blank LTCC test samples are shown in
Figure 16. When comparing Blank test samples that were soaked in DI H2O
(“Leached”) to those that were not (“Unleached”), the images show that soaking
in DI H2O facilitated in cellular attachment and spreading. The images show
more HUVECs spread onto the leached samples indicating healthier cells for
growth and attachment. The data in Figure 17A shows no significant decrease
in viability of the HUVECs on each of the Blank LTCC materials. However, the
data in Figure 17B shows significant decreases in the number of cells per area
when compared to the control well. The data in Figure 17B also illustrates an
increase in the number of HUVECs per area in the leached test samples over the
unleached test samples. Figure 17B also exhibits that HUVECs did attach onto
the Blank test samples as well as grow on the surface as exhibited by the
increase in the number of cells per area from Day 1 to Day 3. Therefore,
HUVECs spread and grew better onto leached Blank LTCC test samples
compared to unleached Blank LTCC test samples.
B-ii. HUVEC ATTACHMENT AND GROWTH ON CONDUCTIVE PASTES
The biocompatibility results for both Silver and Gold conductive pastes
were very favorable for TEER applications. The viability of the HUVECs grown
on both pastes was similar to those of the control wells as demonstrated in
Figure 18A and 18C. Both Silver and Gold test samples show a significant
decrease in cell density compared to that of the control wells after one day of
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Figure 16: Images of HUVECs on Blank LTCC test samples at (A) Initial
Attachment, (B) one day cell culturing, or (C) three days of cell culturing on
either (1) unleached or (2) leached samples
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Figure 17: Biocompatibility results for unleached and leached Blank LTCC test
samples (A) percentage of viable HUVECs compared to the control group
(B) Cells/area compared to the control group; *p<0.05
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Figure 18: Biocompatibility results for unleached and leached Gold LTCC test
samples (A) percentage of viable HUVECs compared to the control group
(B) Cells/area compared to the control group as well as Silver LTCC test
samples (C) percentage of viable HUVECs compared to the control group
(D) Cells/area compared to the control group; *p<0.05
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culturing HUVECs. However, the HUVECs on both of the conductive pastes
demonstrated similar growth to the control after three days of culturing. The data
in Figure 18 indicates that both unleached and leached test samples for the
conductive inks were similar to each other in both viability and cells per area.
The only exception was that the unleached Silver sample set on the third day
showing significantly higher cells per area than both the control and its leached
counterpart. The Figure 18 data also shows inconsistency of cell growth on the
Silver samples as the data of cells per area went down in day 1 but shot up in
day 3. The images in Figure 19 (C-1) confirmed a high cell density onto the
unleached Silver LTCC sample by the displaying a nice confluent monolayer of
HUVECs on the surface of the test samples after three days of culturing. Images
from both conductive pastes (Figure 19 and Figure 20) are in agreement with the
blank sample set and show more spreading of the HUVECs on the leached
samples compared to those of the unleached samples. Therefore, these studies
demonstrate the benefit of a leaching period as indicated by the HUVECs ability
to attach and grow properly along the surface of conductive pastes in which this
occurs.
B-iii. CONFLUENT HUVEC MONOLAYER INSIDE CHANNEL OF LTCC
DEVICE
The results from this study show that a confluent HUVEC monolayer can
be obtained within the channel of an LTCC system that was soaked in
fibronectin. The images obtained from this study display a viable endothelial cell
monolayer on both the LTCC bare ceramic material as well as the gold
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Figure 19: Images of HUVECs on Silver LTCC test samples at (A) Initial
Attachment, (B) one day cell culturing, or (C) three days of cell culturing on
either (1) unleached or (2) leached samples
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Figure 20: Images of HUVECs on Gold LTCC test samples at (A) Initial
Attachment, (B) one day cell culturing, or (C) three days of cell culturing on
either (1) unleached or (2) leached samples

54

Figure 21: Images of confluent HUVEC monolayer inside an LTCC channel
containing two rectangular gold electrodes
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conductive paste used to make the rectangular electrodes (Figure 21). This
further supports the idea that these materials can be used to test endothelial cells
with electronic applications such as TEER while the cells are exposed to a more
physiological environment. With a device like this, endothelial cells can be
exposed to shear stresses that would augment the cells in the direction of fluid
flow as well as take TEER measurements.
B-iv. LTCC DEVICE SYSTEM PERFORMANCE COMPARISON
The instrument detection limit (IDL) is the smallest signal differentiated
from the background noise of a system. It is calculated by taking three standard
deviations. The IDL is used to compare different instruments. The IDL data in
Figure 23 indicates the Endohm12 TEER cup with the EVOM2 Voltohmmeter is
the most precise instrument followed by the LTCC TEER device with the Inhouse system and lastly the STX2 chopsticks. However, the data in Figure 22
also shows that the LTCC TEER device performed better than the Endohm12
TEER cup when the cup was connected to the In-house system the LTCC TEER
device was using. This data reveals that the LTCC device is suitable for the
detection of an endothelial cell monolayer. The LTCC device performance is also
mirroring that of the commonly used and reliable Endohm12 TEER cup.
B-v. IMPROVED IMPEDANCE RESPONSES
Electrical impedance experiments, using standard circuit elements to
simulate the response and characteristics of a cultured cell monolayer, confirm
the ability to isolate and accurately measure the expected changes in cellular
permeability occurring in the sensor array. To confirm that the sensors were
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Figure 22: Instrument detection limits and anticipated
endothelial cell monolayer values (dotted lines)
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sensitive enough to detect the expected impedance values of a HUVEC
monolayer, a preliminary study was conducted on two ceramic chips. One chip
was constructed with an electrode array of 4mm2, while the other was 0.05mm2.
The channel of these chips was then filled with media and background
impedance measurements were obtained. Afterwards, a circuit was attached to
the chips to mimic an EC monolayer and impedance measurements were
obtained. Results indicate that by decreasing the size of the electrode, the
double layer capacitance caused by the media-electrode interface could be
overcome (Figure 23). Figure 23 also illustrates an improvement isolating the
contributions of the cell layer from the interfacial effects for the small electrode
(B) as opposed to the larger electrode (A). Previous experiments have also
shown an improvement in system sensitivity by reducing electrode size and
adding in a lock-in amplifier. This resulted in the detection limit of the ceramic
device to drop to 0.198 Ω*cm2 (see Figure 24). This allows for effective
determination of minimal changes (~1-2% of a HUVEC monolayer, 10-20
Ω*cm2)78-80 in the permeability of the EC monolayer being analyzed within the
device.
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Figure 23: Graphs showing impedance values of a ceramic device with a
4mm2(A) and 0.05mm2(B) electrode array exposed to media (open dots) and
a parallel resistor and capacitor to mimic a cell monolayer (closed dots) at
varying frequencies
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Figure 24: Instrument detection limits with lock-in amplifier and
LTCC device with smaller electrode array (New) and without (Old)
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C. DISCUSSION
The results from the HL2000 biocompatibility studies indicate a poor initial
attachment of endothelial cells to Blank LTCC surfaces followed by growth of
endothelial cells once initially attached. These experiments also show attachment
and growth of endothelial cells on top of conductive pastes used by LTCC
devices. The minimal differences in biocompatibility between “leached” and
“unleached” LTCC materials suggest leachates do not deter HUVEC proliferation
and growth on LTCC materials. However, HUVECs are shown to spread easier
along the surface of these LTCC materials after a 24 hour soak period in DI
water was employed. These experiments have also shown the performance of
an LTCC TEER-based device. This device expands the application of TEER
measurements into a microfluidic platform, with improved detection limits
compared to static cell culture well experiments. HUVECs were also shown to
attach and grow confluently within the channel of an LTCC-based device.
Improvements have also been made and shown to aid in the detection of TEER
response within the device.
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CHAPTER 5
CONCLUSION
This research has introduced a possible new approach to better define
and detect SIRS/sepsis. Initial results show a rapid, significant difference
between healthy and extremely septic TEER values in the rat CLP model.
Following the analysis of varying SIRS-rated serums, a more delayed response
in TEER values was found. Even though this large static model was unable to
display a statistical difference amongst the different SIRS-rated serums,
measurements can be improved and optimized through electrode geometry, cell
type, and environment in which the cells are analyzed. The mechanisms in
which endothelial cell junctions are disrupted due to SIRS/sepsis is quite
complex and poorly understood today. There is still a need for a better definition
and early detection of this disease. The ELISA assays displayed an insight into
the TEER response and further indicates the complexity of this disease.
Research also looked into the use of low temperature co-fired ceramics as a
potential microfluidic base that can incorporate 3-D microstructures and electrical
applications. This research shows biocompatibility of endothelial cells on LTCC
materials as well as improved measurements for impedance testing. Therefore,
a foundation for cell based “in-vitro” devices using LTCC materials has been
established. Due to the nature in which endothelial cells are affected by
SIRS/sepsis, an LTCC TEER-based microfluidic device has the potential to
detect varying degrees of SIRS and aid in a more effective treatment strategy for
patients thereby potentially saving lives.
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RECOMMENDATIONS
This research does not analyze cells in their natural environment.
Therefore, the construction of a microfluidic device is recommended;
incorporating an array of confluent EC-based sensors that monitor electrical
impedance changes would be the most beneficial and practical approach to
expanding into the biomedical industry. Generating such a device will allow for
testing of the endothelial cells in a more natural fluidic environment. The
incorporation of a smaller electrode in such a device will produce larger
impedance values while analyzing a smaller group of cells. A greater sensitivity
will be achieved when compared to the static studies displayed in this research.
Microfluidic technology will enable continuous aseptic testing of EC permeability
with the capability of automated results.
Furthermore, research has shown that different cell lines within the
endothelium use different pathways to respond to inflammation.13 These cells
also contain different amounts of protein complexes within the TJs and AJs. 80-87
Therefore, the impedance responses of these cells will differ amongst the varying
inflammatory agents associated with SIRS/sepsis. It is recommended that future
research looks into the impedance effects of different endothelial cell lines to the
inflammatory agents associated with SIRS/sepsis to determine the most effective
cell line for use in the impedance device.
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APPENDICES
Appendix A: Abbreviations
Systemic inflammatory response syndrome …………………..………(SIRS)
Endothelial cell ………………………………………..…………………….(EC)
Low temperature co-fired ceramic …………………………….……....(LTCC)
Adheren junction …………………………………………………………….(AJ)
Tight junction ………………………………………………………………...(TJ)
Junction associated molecule …………………………………………...(JAM)
Zonula occludens …………………………………………………………..(ZO)
Vascular endothelial ………………………………………………………..(VE)
E-Twenty Six ………………………………………………………………(ETS)
Human dermal microvascular endothelial cell ……………………(HDMEC)
Human umbilical vein endothelial cell ………………………………(HUVEC)
Vascular endothelial growth factor …………………………………....(VEGF)
Tumor necrosis factor …………………………………………………….(TNF)
Interleukin ……………………………………………………………………..(IL)
Multiple organ dysfunction syndrome ………………………………..(MODS)
Cecal litigation and puncture …………………………………………….(CLP)
Acute physiology and chronic health evaluation …………………(APACHE)
Procalcitonin ……………………………………………………………….(PCT)
C-Reactive Protein ……………………………………………………….(CRP)
Sequential organ failure assessment …………………………………(SOFA)
Polydimethylsiloxane……………………………………………………(PDMS)
Fluorescein isothiocyanate conjugated…………………………………(FITC)
Transendothelial electrical resistance…………………………………(TEER)
Electrical cell substrate impedance spectroscopy…………………….(ECIS)
Electrochemical impedance spectroscopy……………………………….(EIS)
Ion sensitive electrode……………………………………………………..(ISE)
Dulbecco’s phosphate-buffered saline………………………………...(DPBS)
Granulocyte/macrophage colony stimulating factor………………(GM-CSF)
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